ArticleFrontiers in cell and developmental biology2025
Systematic characterization of cross-source miRNA biomarkers in prostate cancer with computational-experimental integrated analysis.
Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Prostate cancer (PCa) is occult and remains largely incurable once it metastasizes. Our research aims to identify the key miRNAs and construct miRNA-mRNA networks for PCa. Methods: The microarray dataset GSE112264, consisting of 1,591 male serum samples, and tissue miRNA data from TCGA, including 497 prostate cancer and 52 normal samples, were included in the analysis. Differentially expressed miRNAs (DE-miRNAs) were detected, and miRTarBase was used to predict the common target genes. Then, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed for the target genes. The protein-protein interaction (PPI) network, which revealed the top 10 hub genes, was constructed using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) and Cytoscape. The expression of the potential hub genes was examined using the UALCAN database. Finally, GSE112264, TCGA datasets, and clinical samples were used to verify the consistency of miRNA expressions in serum and tissue. Results: A total of 948 target genes of the two overlapped downregulated miRNAs (miR-146a-3p and miR-136-3p) were predicted. Functional enrichment analysis indicated that significant DE-miRNAs were related to PCa-related pathways, such as protein binding, the mammalian target of rapamycin (mTOR) signaling pathway, and porphyrin and chlorophyll metabolisms. Four hub genes were identified from the PPI network, namely, NSF, HIST2H2BE, IGF2R, and CADM1, and verified to be aberrantly expressed in the UALCAN database. Experiment results indicated that only miR-136-3p was markedly reduced in both serum and tissue. Conclusion: In this study, we established the miRNA-mRNA network, offering potential PCa targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.